Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation
- 1 April 2020
- journal article
- research article
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 35 (4), 779-786
- https://doi.org/10.1111/jocs.14458
Abstract
Background Extracorporeal membrane oxygenation (ECMO) induces hemostatic alterations that may contribute to hematological complications. Unfractionated heparin (UFH) is the mainstay antithrombotic in ECMO and depends on antithrombin III (AT III) to exhibit its actions. However, it bears the risk for heparin-induced thrombocytopenia. Bivalirudin is a direct thrombin inhibitor and is inherently not dependent on AT III. Aim of the Study To assess the efficacy and safety profiles of UFH compared with bivalirudin during ECMO support. Methods We retrospectively reviewed 52 adult patients who were supported by ECMO from 1 January 2013 to 1 September 2018. Among them, 33 received UFH and 19 received bivalirudin. We analyzed their 7-day rate of composite thrombotic, bleeding, and mortality episodes while on anticoagulation. Results There were no statistical differences in the 7-day rate of composite thrombosis (33.3% vs 26.3%; P = 0.60), major bleeding (18.2% vs 5.3%; P = .24), 30-day mortality, (42.4% vs 26.3%; P = .37), or in-hospital mortality (45.5% vs 36.8%; P = .58). The percentage of time activated partial thromboplastin time (aPTT) was within the therapeutic range was higher with bivalirudin (50% vs 85.7%; P = .007). Conclusions This study suggests that UFH and bivalirudin are associated with similar rates of thrombosis, major bleeding, and mortality events in patients supported by ECMO. However, it was observed that bivalirudin consistently maintained aPTT within the therapeutic range in comparison to UFH.Keywords
This publication has 10 references indexed in Scilit:
- Evaluation of Systemic Heparin Versus Bivalirudin in Adult Patients Supported by Extracorporeal Membrane OxygenationAsaio Journal, 2018
- Accurate costs of blood transfusion: a microcosting of administering blood products in the United Kingdom National Health ServiceTransfusion, 2018
- Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic ReviewJournal of Intensive Care Medicine, 2016
- Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and ChildrenThe Journal of Pediatric Pharmacology and Therapeutics, 2015
- Bivalirudin Versus Heparin as an Anticoagulant During Extracorporeal Membrane Oxygenation: A Case-Control StudyJournal of Cardiothoracic and Vascular Anesthesia, 2013
- Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenationCritical Care, 2011
- Heparin induced thrombocytopenia: diagnosis and management updatePublished by Oxford University Press (OUP) ,2007
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Evaluation of Bivalirudin Treatment for Heparin-Induced Thrombocytopenia in Critically Ill Patients with Hepatic and/or Renal DysfunctionPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Bivalirudin: A Direct Thrombin Inhibitor for Percutaneous Transluminal Coronary AngioplastyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002